Cardlytics, Inc. (NASDAQ:CDLX) Given Average Recommendation of “Hold” by Brokerages

Cardlytics, Inc. (NASDAQ:CDLX) has been assigned an average recommendation of “Hold” from the seven ratings firms that are covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, five have assigned a hold recommendation and one has assigned a strong buy recommendation to the company. The average 12 month target price among analysts that have covered the stock in the last year is $6.92.

Several research analysts have commented on CDLX shares. Evercore ISI began coverage on shares of Cardlytics in a report on Friday, October 11th. They set an “in-line” rating and a $4.00 price target for the company. Craig Hallum upgraded shares of Cardlytics from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, November 6th. Finally, Needham & Company LLC restated a “hold” rating on shares of Cardlytics in a research note on Friday, January 17th.

Cardlytics Trading Up 3.7 %

CDLX opened at $3.12 on Thursday. The business has a fifty day moving average price of $3.56 and a 200 day moving average price of $4.07. The company has a debt-to-equity ratio of 2.40, a current ratio of 1.18 and a quick ratio of 1.18. Cardlytics has a 12 month low of $2.76 and a 12 month high of $20.52. The stock has a market capitalization of $158.56 million, a price-to-earnings ratio of -0.51 and a beta of 1.54.

Cardlytics (NASDAQ:CDLX) last announced its quarterly earnings data on Wednesday, November 6th. The company reported ($0.15) EPS for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.18. The business had revenue of $67.06 million during the quarter, compared to the consensus estimate of $57.77 million. Cardlytics had a negative return on equity of 110.67% and a negative net margin of 93.55%. The business’s revenue for the quarter was down 15.1% on a year-over-year basis. During the same period in the previous year, the company posted ($0.26) earnings per share. Sell-side analysts expect that Cardlytics will post -1.52 earnings per share for the current fiscal year.

Insider Activity at Cardlytics

In other news, CFO Alexis Desieno sold 8,854 shares of Cardlytics stock in a transaction dated Friday, January 3rd. The stock was sold at an average price of $3.67, for a total transaction of $32,494.18. Following the sale, the chief financial officer now owns 121,976 shares in the company, valued at approximately $447,651.92. The trade was a 6.77 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Amit Gupta sold 15,160 shares of the company’s stock in a transaction dated Friday, January 24th. The shares were sold at an average price of $3.92, for a total value of $59,427.20. Following the completion of the sale, the chief executive officer now directly owns 215,494 shares of the company’s stock, valued at approximately $844,736.48. This trade represents a 6.57 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 64,937 shares of company stock valued at $234,460 over the last ninety days. Insiders own 4.40% of the company’s stock.

Hedge Funds Weigh In On Cardlytics

A number of hedge funds have recently modified their holdings of the business. XTX Topco Ltd acquired a new stake in Cardlytics during the 2nd quarter worth $107,000. SG Americas Securities LLC purchased a new stake in shares of Cardlytics in the third quarter valued at about $45,000. Creative Planning boosted its stake in shares of Cardlytics by 35.4% during the third quarter. Creative Planning now owns 29,537 shares of the company’s stock worth $95,000 after buying an additional 7,721 shares during the period. Acorn Financial Advisory Services Inc. ADV grew its holdings in shares of Cardlytics by 40.5% during the third quarter. Acorn Financial Advisory Services Inc. ADV now owns 164,409 shares of the company’s stock worth $526,000 after buying an additional 47,358 shares during the last quarter. Finally, GSA Capital Partners LLP increased its position in Cardlytics by 1,273.2% in the 3rd quarter. GSA Capital Partners LLP now owns 382,315 shares of the company’s stock valued at $1,223,000 after acquiring an additional 354,474 shares during the period. 68.10% of the stock is currently owned by hedge funds and other institutional investors.

Cardlytics Company Profile

Cardlytics, Inc operates an advertising platform in the United States and the United Kingdom. It offers Cardlytics platform, a proprietary native bank advertising channel that enables marketers to reach customers through their network of financial institution partners through digital channels, such as online, mobile applications, email, and various real-time notifications; and Bridg platform, a customer data platform which utilizes point-of-sale data and enables marketers to perform analytics and targeted loyalty marketing, as well as measure the impact of their marketing.